menu
    • menu
    [{"orgOrder":0,"company":"Translational Genomics Research Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atovaquone","moa":"Cytochrome b","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Translational Genomics Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Genomics Research Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Translational Genomics Research Institute \/ Not Applicable"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Atovaquone","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Quotient Sciences \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"12","companyTruncated":"Quotient Sciences \/ Medicines for Malaria Venture"}]

    Find Clinical Drug Pipeline Developments & Deals for Atovaquone

    Menu

    Atovaquone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quotient Sciences

                            United Kingdom
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quotient Doses Volunteers in Malaria Venture’s Long-Acting Injectable Prevention Study

                            Details : MMV371 is a prodrug of atovaquone (selective inhibitor of cytochrome bc1 complex), ben investigated for malaria in adults.

                            Brand Name : MMV371-Prodrug

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 28, 2024

                            Lead Product(s) : Atovaquone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Medicines for Malaria Venture

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Translational Genomics Research Institute

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Translational Genomics Research Institute

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atovaquone,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TGen and HonorHealth trial atovaquone plus azithromycin for Covid-19

                            Details : Atovaquone plus azithromycin combination was studied in other infectious disease and is expected to offer a well-tolerated option for patients infected with the novel coronavirus.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 06, 2020

                            Lead Product(s) : Atovaquone,Azithromycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth